At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,672 enrolled
Drug / intervention
Ubrogepant +1 moredrug
Likely dose
Ubrogepant 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Ubrogepant and Placebo-matching Ubrogepant for Migraine, With or Without Aura. Completed, enrolled 1,672 participants across 90 sites.
Detailed Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartJul 2016
Primary CompletionDec 2017
Study CompletionDec 2017
TodayJul 2026
First PostedJul 11, 2016
Enrollment StartJul 22, 2016
Primary CompletionDec 13, 2017
Study CompletionDec 14, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago
Interventions
Ubrogepantdrug
50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepantdrug
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.